tbuckley/cabot-search huggingface dataset:
The role of <scp>S</scp>taphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration
Authors: H. Fujishima, N. Okada, M. Dogru, F. Baba, M. Tomita, J. Abe, K. Matsumoto, H. Saito
Journal: Allergy (2012)

Patients with atopic eczema frequently experience colonization with Staphylococcus aureus that is directly correlated with the eczema severity. We hypothesized that S. aureus-secreted enterotoxins (SE) are involved in the pathophysiology of atopic keratoconjunctivitis (AKC).A total of 45 subjects (18 with AKC, nine vernal keratoconjunctivitis (VKC), eight seasonal allergic conjunctivitis (SAC), and ten healthy volunteers) were enrolled. Slit lamp examinations, including fluorescein staining, were performed. Scraped samples were collected from the upper tarsal conjunctiva, lower conjunctival sacs, and the skin around the eyelid margins. Superantigen (SAg) genes were detected using polymerase chain reaction (PCR).Among 45 cases, S. aureus was detected significantly more in AKC patients than VKC patients (P = 0.026), SAC patients (P = 0.0003), and healthy volunteers (P = 0.0001). SAg genes were detected in 11 patients. SEB (2/11), SEG (8/11), and SEI (8/11) were detected, but no other SE. There was a significant difference in SE detection between AKC and SAC patients (P = 0.03). In severe types of ocular allergic disease such as AKC and VKC (N = 27), SE was detected in six of ten patients with corneal ulcers and two of 17 patients without corneal ulcers. SE was detected in significantly more patients with corneal ulcers (P = 0.025).In patients with AKC, S. aureus and SE were detected more frequently compared with other patients and healthy volunteers, especially in association with corneal ulceration suggesting a role of SE. So far, it is unknown whether SE leads to tissue damage of the cornea by initiating an immune response or has direct toxic effects.
Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)
Authors: Saro H. Armenian, Can-Lan Sun, Toana Kawashima, Mukta Arora, Wendy Leisenring, Charles A. Sklar, K. Scott Baker, Liton Francisco, Jennifer Berano Teh, George Mills, F. Lennie Wong, Joseph Rosenthal, Lisa R. Diller, Melissa M. Hudson, Kevin C. Oeffinger, Stephen J. Forman, Leslie L. Robison, Smita Bhatia
Journal: Blood (2011)
Network models of psychopathology and comorbidity: Philosophical and pragmatic considerations
Authors: S. Brian Hood, Benjamin J. Lovett
Journal: Behavioral and Brain Sciences (2010)

Abstract Cramer et al.'s account of comorbidity comes with a substantive philosophical view concerning the nature of psychological disorders. Although the network account is responsive to problems with extant approaches, it faces several practical and conceptual challenges of its own, especially in cases where the individual differences in network structures require the analysis of intra-individual time-series data.
Stapling Muscle Biopsy Specimens to Prevent Artifcats
Authors: Irwin M. Siegel
Journal: JAMA (1988)

<h3>To the Editor.—</h3> Open-muscle biopsy specimens often are clamped to prevent contraction artifacts, particularly when they are to be processed for electron microscopy. Instruments available for this may be expensive to purchase, difficult to use, or simply unobtainable in the average operating room. Another method is to stretch the muscle on a tongue blade and tie it down with heavy sutures. This can prove to be tedious and time consuming. An alternative technique is to staple the free specimen to a strip of balsa wood (standard size, 5×2 mm, obtainable for pennies at any hobby shop) that has been cut into short lengths with a razor blade. A surgical skin stapler, ready for disposal after use but still containing a few staples, is ideal for this procedure. The staple grips the specimen and strip of balsa circumferentially. As it is tightened, the muscle is held firmly to the wood, preventing
Biventricular Cardiac Thrombosis during Interleukin-2 Infusion
Authors: R.P. Junghans, W. Manning, M. Safar, W. Quist
Journal: New England Journal of Medicine (2001)

To the Editor: We report on the phenomenon of intracardiac thrombosis with features of Loffler's syndrome observed in conjunction with interleukin-2 therapy. Patient 1, a 26-year-old woman with stage IV Hodgkin's disease, began to receive a continuous infusion of recombinant human interleukin-2 (aldesleukin; Proleukin, Chiron) in an experimental outpatient protocol; the initial dose was 75,000 IU per kilogram of body weight per day and was increased weekly, as tolerated, to a maximum of 150,000 IU per kilogram per day. The patient had a corresponding increase in eosinophils in peripheral blood to a maximum of 11,400 cells per cubic millimeter. On . . .
The enteric nervous system in health and disease
Authors: M COSTA
Journal: Gut (2000)

The purpose of this workshop was to bring together scientists pursuing fundamental research into the physiology and pharmacology of the enteric nervous system (ENS) and clinical researchers concerned with drug development for gastrointestinal disease management. The planning of the programme was undertaken by a core group of gastroenterologists and researchers, namely Arnold Berstad, Hans Glise, Hans Graffner, Michael Kamm, Denis McCarthy, and Rune Sjodahl, and the meeting provided a …
477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES
Authors: M.S. Sulkowski, R. Reddy, N.H. Afdhal, A.M. Di Bisceglie, S. Zeuzem, F. Poordad, L. Bengtsson, C.I. Wright, R.S. Kauffman, N. Adda
Journal: Journal of Hepatology (2011)
Off-Label Uses of Anticancer Drugs-Reply
Authors: Charles G. Moertel
Journal: JAMA (1992)

<h3>In Reply.</h3> —In criticism of my Editorial, Dr Abeloff states that I equated off-label cancer therapy with lack of effectiveness. A more careful reading will show that I documented several circumstances of fully justified off-label prescribing. However, in reviewing the General Accounting Office listing of resistant cancers commonly treated off-label and drugs most commonly used, I feel Abeloff would be hard pressed to cite convincing evidence that any but a very few of these approaches do, indeed, produce palliative benefit that is quite meaningful to patients. Such evidence would seem mandatory before we subject desperate patients to the major toxicity and extraordinarily high costs that these approaches may involve. Abeloff and I agree that serious abuses of our health care system involving off-label prescribing exist. In some instances these have been so profitable that patients and families are offered free air transportation, contingent, of course, on evidence of coverage for
The Need for Unified Medical Management of Interictal Personality Changes
Authors: Vernon H. Mark
Journal: JAMA (1976)

Increasing specialization in medicine may bring hazards as well as benefits to the patient whose complaints do not fall into the typical pattern of medical disease. He or she may be called a "crock," sent to a psychiatrist for management, and then suffer the results of little or no communication between the referring physician and the psychiatrist. Nowhere is this practice more unfortunate than when it occurs in an emotionally disturbed patient who also has symptoms of structural or functional brain disease. Waxman and Geschwind illustrate this clearly in their article in the recent issue of<i>Archives of General Psychiatry</i>(32:1580-1586, 1975). They point out that some patients with temporal lobe epilepsy, especially when it involves the limbic system, may have changes in their behavior that occur between obvious seizures. They describe hyperreligiosity, punctuated by religious conversions; hypergraphia, characterized by strikingly voluminous writings of an unusually compulsive nature; and occasional
Estimating Overdiagnosis in Lung Cancer Screening
Authors: Pamela M. Marcus
Journal: JAMA Internal Medicine (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The predictive probability of four different breast cancer nomograms for non-sentinel axillary lymph node metastasis in positive sentinel lymph node biopsy.
Authors: SA Gur, B Unal, R Johnson, G Ahrendt, M Bonaventura, A Soran
Journal: Cancer Research (2009)

Abstract Abstract #204 Introduction: Although completion axillary lymph node dissection (CALND) is the standard for evaluating axillary status after identification of a positive sentinel lymph node (SLN) in breast cancer (BC), almost 50% of SLN positive patients will have negative non-SLN and undergo a non-therapeutic axillary dissection. Accurate estimates of the likelihood of additional disease in the axilla can assist decision-making about further treatment. In order to predict non- sentinel lymph node metastases (NSLNM) in patients with a positive SLN biopsy, four different nomograms have been created. The Memorial Sloan Kettering Cancer Center (MSKCC) nomogram was created in 2003 and validated at sources outside that institution. The other nomograms were developed by the Tenon Hospital, the Cambridge University and the Stanford University group recently, but have not been validated yet. The aim of this study was to evaluate the accuracy of 4 different nomograms in our SLN positive BC patients. Methods: We identified 319 patients who had a positive SLN biopsy and CALND at Magee-Womens Hospital of the University of Pittsburgh Medical Center over an 8 year period. The BC nomograms developed by the MSKCC, the Tenon Hospital, the Cambridge University and the Stanford University were used to calculate the probability of NSLNM. Area Under (AUC) Receiver Operating Characteristics Curve (ROC) was calculated for each nomogram a value more than 0.70 was accepted as providing considerable discrimination. Results: One hundred-seven of 319 patients (33.5%) had positive axillary NSLNM. The mean predicted probability of positive NSLNM was 28.1 % (3-93), 67.1% (4.8-100) and, 39.1% (3.6-97.5) for the MSKCC, the Cambridge, and the Stanford nomograms, respectively. The mean point for the Tenon model was 4.45 (0-7). The AUC values were 0.70, 0.69, 0.69 and 0.64 for the MSKCC, the Tenon, the Cambridge and, the Stanford models, respectively. Conclusion: Breast nomograms can be used in the current practice to provide an accurate prediction for identifying low or high risk for NSLNM in BC. In our study, we found the MSKCC nomogram is more predictive than the other nomograms but the Cambridge model and the Tenon model reached borderline values for the good prediction. A model can provide more accurate results with its original group, but may be insufficient on the different groups. Nomograms developed at other institutions should be used with caution when counseling patients regarding the risk of additional nodal disease. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 204.
G‐CSF enhanced granulocyte production in a child with severe neutropenia in the setting of fatal virus‐associated hemophagocytic syndrome
Authors: Eiichi Azuma, Nobutada Tabata, Takeo Shibata, Yoshihiro Komada, Masahiro Ito, Minoru Sakurai, Shin‐Ichiro Atsumi, Yoko Kawasaki, Masahiko Ishii
Journal: American Journal of Hematology (1990)

Abstract A 14‐year‐old boy with fatal varicella zoster virus‐associated hemophagocytic syndrome (VAHS) was treated with recombinant human granulocyte colony‐stimulating factor (G‐CSF) based on the finding that the patient had severe neutropenia and possible bacterial superinfection. Support for the G‐CSF therapy in VAHS is provided by the recent reports that G‐CSF is relatively specific for the granulocyte lineage; it would not activate mature monocyte/macrophage/histiocyte lineage in VAHS, where the most striking morphologic feature is histiocytic hyperplasia with hemophagocytosis. He responded well to G‐CSF with an elevation of neutrophil counts. There were no effects on other blood cells. The result indicates that G‐CSF is useful to increase granulocyte production in severe neutropenia, even in the setting of fatal VAHS.
CYP-omega-hydroxylation-dependent metabolites of arachidonic acid inhibit the basolateral 10pS chloride channel in the rat thick ascending limb
Authors: Rui-Min Gu, Lei Yang, Yunhong Zhang, Lijun Wang, Shumin Kong, Chengbiao Zhang, Yuanyuan Zhai, Mingxiao Wang, Peng Wu, Liping Liu, Feng Gu, Jiye Zhang, Wen-Hui Wang
Journal: Kidney International (2009)
CDC Recommendations for Opt-Out HIV Testing
Authors: David R. Holtgrave
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Protease Variants, LDL, and Coronary Heart Disease
Authors: Alan R. Tall
Journal: New England Journal of Medicine (2006)

Just when we thought we understood everything about low-density lipoprotein (LDL) cholesterol and its relationship to cardiovascular risk, along comes a discovery that reveals a new control mechanism and suggests a strategy for the prevention of atherosclerotic cardiovascular disease.Plasma levels of LDL cholesterol are in large part determined by the activity of LDL receptors in the liver. Autosomal dominant familial hypercholesterolemia — with its high levels of LDL cholesterol, xanthomas, and premature atherosclerosis — is caused by mutations either in the gene encoding the LDL receptor or in the gene encoding apolipoprotein B — the protein in LDL cholesterol . . .
Cost-effective roles for nurse practitioners in secondary prevention
Authors: Robert L Phillips, Jessica McCann
Journal: BMJ (2005)

Who pays and who saves may stymie implementation in the US 

I n this issue (p 211), Raftery et al report on a cost-effectiveness analysis of a now 10 year-old randomized controlled trial of nurse-led secondary prevention for coronary heart disease. This analysis is timely for the UK because up to 20% of physician income is now tied to performance measures.1 It is similarly relevant in the US, given our current interest in pay-for-performance, disease management, and the development of health care teams. It offers cost-effectiveness evidence for an enhanced nursing role in primary care, but the differing locations of the cost and the savings may make implementation difficult in the US.

> The study by Raftery et al relates to an increased focus on team-based care that is patient-centered and breaks free from physician visits as the locus of care. 

The investigators have previously reported on the successes of this intervention for improved secondary prevention and for health-related quality of life. The study, done in Scotland, randomized patients within general practice …
SPREADING PROPERTY OF AZOPROTEINS IN THE DERMIS
Authors: Albert Claude
Journal: The Journal of Experimental Medicine (1935)

1. Azoproteins are shown to have the property of spreading when introduced intradermally into the rabbit skin. 2. The aromatic derivative selected for the coupling does not affect specifically the spreading property of the azoprotein. Likewise, the type of protein has no importance, except in quantitative respects. 3. The spreading property conferred upon a protein by coupling appears to derive from the presence of the azo group. 4. The spreading power of an azoprotein preparation seems to be determined by the number of diazo groups which enter the protein molecule, and to vary in direct proportion with the concentration of the solution. 5. Azo compounds of low molecular weight fail to exhibit any significant effect on skin permeability.
Racial differences in the relationship between hepatitis C infection and iron stores
Authors: George N. Ioannou, Jason A. Dominitz, Noel S. Weiss, Patrick J. Heagerty, Kris V. Kowdley
Journal: Hepatology (2003)

Black race and increased hepatic iron stores predict poor response to interferon treatment for chronic hepatitis C virus (HCV) infection. We tested the hypothesis that these 2 observations are linked by investigating whether HCV–infected African–Americans have increased iron stores relative to uninfected persons. Using data from the third National Health and Nutrition Examination Survey (NHANES III), we determined the risk of having increased iron stores, defined as elevation of both serum ferritin and transferrin–iron saturation (TS), in HCV–RNA–positive blacks (n = 100) and nonblacks (n = 126) relative to HCV–RNA–negative blacks (n = 4,002) and nonblacks (n = 10,943). HCV–positive blacks were 5.4 times (95% CI, 1.2 to 24) more likely to have increased iron stores than HCV–positive nonblacks. The proportion of HCV–positive blacks who had increased iron stores was 16.4% among those with abnormal liver enzymes and 2.8% among those with normal liver enzymes, compared with only 0.6% among HCV–negative blacks. After adjustment for age, alcohol intake, gender, menopausal status, education, body mass index, and poverty index, HCV–positive blacks with abnormal liver enzymes had an elevated risk of having increased iron stores (odds ratio, 17.8; 95% CI, 5.1 to 63). In contrast, among persons of other races, there was a much smaller difference in the proportion of persons with increased iron stores between HCV–positive persons with (3.4%) or without (1.4%) abnormal liver enzymes and HCV–negative persons (0.9%). In conclusion, a greater proportion of blacks than persons of other races respond to HCV infection with an increase in iron stores. This finding may partly explain the reduced response of HCV–positive African–Americans to antiviral treatment. (Hepatology 2003;37:795–801.)
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Authors: P. Imbach, V. d'APUZZO, A. Hirt, E. Rossi, M. Vest, S. Barandun, C. Baumgartner, A. Morell, M. Schöni, H.P. Wagner
Journal: The Lancet (1981)
Commitment Devices
Authors: Todd Rogers, Katherine L. Milkman, Kevin G. Volpp
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A skin disease, a blood disease or something in between? An exploratory focus group study of patients' experiences with porphyria cutanea tarda
Authors: J. Andersen, E. Gjengedal, S. Sandberg, M. Råheim
Journal: British Journal of Dermatology (2014)

BackgroundPorphyria cutanea tarda (PCT) is characterized by fragile skin with blistering on sun‐exposed areas. Symptoms typically develop in late adulthood and can be triggered by iron overload, alcohol intake, oestrogens and various liver diseases. Treatment consists of phlebotomy to reduce iron, or increasing urinary porphyrin excretion by administering chlorochin. To optimize patient care, health personnel need to understand the subjective experiences of PCT.
Results of large scale media antismoking campaign in Australia: North Coast "Quit for Life" programme.
Authors: G Egger, W Fitzgerald, G Frape, A Monaem, P Rubinstein, C Tyler, B McKay
Journal: BMJ (1983)

A three community study was carried out in northern New South Wales, Australia, to determine the effectiveness of interventions via media and media plus community programmes in altering behaviours of life style, including smoking, dietary fat intake, and exercise. Results were analysed of one aspect of the "North Coast Healthy Lifestyle Programme" entitled "Quit for Life," which aimed at reducing cigarette smoking over a two year period. There was a significant decline in the prevalence of smoking in both test towns, ranging from 16% in younger men to 6% in older women. These were significantly greater than the declines in the control town. The declines were more sustained over the two year period in the town subjected to media plus community programmes.